Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097687 | 1.00 | GAA (0.47) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL4660002 | 0.80 | GAA (0.54) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL10500924 | 0.77 | GAA (0.51) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL10343767 | 0.77 | GAA (0.51) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL9276338 | 0.75 | GAA (0.54) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL11306621 | 0.75 | MIF (0.51) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL11306614 | 0.75 | MIF (0.51) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL14196325 | 0.74 | — | — | |
| SCHEMBL23131067 | 0.71 | GAA (0.57) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL17577099 | 0.71 | GAA (0.53) | GAAMIFCYP1A2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1824847-A2 | PYRIDAZINONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060189602-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006066079-A2 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189602-A1 | Pyridazinone compounds | HAVCR2, PLPBP, CYP3A43 | GAA 1751/4885MIF 2929/4885CYP1A2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.